clinical_trials
Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease
Confidence86·multiple reportsImportance88NP-EVT-20261016-EFD2504
(MedPage Today) -- Subcutaneous risankizumab (Skyrizi) induction therapy significantly improved clinical remission and endoscopic response rates in patients with moderately to severely active Crohn's disease, results from the phase III AFFIRM trial...
Read the original at the primary source
Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's Disease
10/16/2026, 5:22:34 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —